Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.
This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.
ADI CEO, Paola Barbarino took to the stage at the ADI 2024 Conference in Krákow, Poland, to highlight the global and national policy landscape on dementia, providing her perspective on the achievements of ADI in the past four decades and hopes for the future.
In April 2024, the world's longest-running global conference on Alzheimer's disease and dementia came to Kraków, Poland, to provide the latest insights, innovations and inspirations on dementia over three days, six plenary sessions, 29 parallel sessions and eight symposiums to over 1000 delegates representing over 100 countries.
From symposiums and conferences to high-level meetings and webinars, ADI delegates around the world have taken part in dynamic global efforts to improve the lives of those living with dementia and carers throughout the month of March.
As we count down the remaining days until the launch of this global event in Kraków, Poland, ADI is proud to share a message from our CEO, Paola Barbarino, and highlight some of our key speakers joining us from 24-26 April 2024.
The EMA regulates the availability of medicines across all 27 European Union Member States as well as Iceland, Norway, and Liechtenstein.